Adam S. Baumgarten
University of South Florida
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adam S. Baumgarten.
Journal of Arthroplasty | 2013
Brian T. Palumbo; Kurt Morrison; Adam S. Baumgarten; Mathew I. Stein; George J. Haidukewych; Thomas L. Bernasek
Evidence supporting modular, tapered stems for severe proximal metaphyseal and diaphyseal bone loss is limited. We report our clinical experience with its use for severely deficient femurs. Of 211 revision total hip arthroplasties (THAs), 18 tapered, modular titanium stems were implanted in Paprosky type III and IV femurs. Clinical data were reviewed for function, stability, structural failure and revision surgery at a mean follow-up of 4.5years. The overall survival rate was 94%. One required revision due to infection and subsidence. The mean subsidence was 3.5mm and the mean pre- and post-operative Harris Hip score was 56 and 79, respectively. In surviving cases, patients achieved satisfactory function and there were no mechanical failures. Modular, tapered stems demonstrated acceptable outcomes for management of severe proximal metaphyseal and diaphyseal defects.
BJUI | 2015
Jared M. Gopman; Rosa S. Djajadiningrat; Adam S. Baumgarten; Patrick Espiritu; Simon Horenblas; Yao Zhu; Chris Protzel; Julio M. Pow-Sang; Timothy Kim; Wade J. Sexton; Michael A. Poch; Philippe E. Spiess
To assess the potential complications associated with inguinal lymph node dissection (ILND) across international tertiary care referral centres, and to determine the prognostic factors that best predict the development of these complications.
Clinical Genitourinary Cancer | 2014
Tariq S. Hakky; Adam S. Baumgarten; Bryan Allen; Hui-Yi Lin; Cesar E. Ercole; Wade J. Sexton; Philippe E. Spiess
BACKGROUND Since the advent of the first standardized renal tumor complexity system, many subsequent scoring systems have been introduced, many of which are complicated and can make it difficult to accurately measure data end points. In light of these limitations, we introduce the new zonal NePhRO scoring system. PATIENTS AND METHODS The zonal NePhRO score is based on 4 anatomical components that are assigned a score of 1, 2, or 3, and their sum is used to classify renal tumors. The zonal NePhRO scoring system is made up of the (Ne)arness to collecting system, (Ph)ysical location of the tumor in the kidney, (R)adius of the tumor, and (O)rganization of the tumor. In this retrospective study, we evaluated patients exhibiting clinical stage T1a or T1b who underwent open partial nephrectomy performed by 2 genitourinary surgeons. Each renal unit was assigned both a zonal NePhRO score and a RENAL (radius, exophytic/endophytic properties, nearness of tumor to the collecting system or sinus in millimeters, anterior/posterior, location relative to polar lines) score, and a blinded reviewer used the same preoperative imaging study to obtain both scores. Additional data points gathered included age, clamp time, complication rate, urine leak rate, intraoperative blood loss, and pathologic tumor size. RESULTS One hundred sixty-six patients underwent open partial nephrectomy. There were 37 perioperative complications quantitated using the validated Clavien-Dindo system; their occurrence was predicted by the NePhRO score on both univariate and multivariate analyses (P = .0008). Clinical stage, intraoperative blood loss, and tumor diameter were all correlated with the zonal NePhRO score on univariate analysis only. CONCLUSION The zonal NePhRO scoring system is a simpler tool that accurately predicts the surgical complexity of a renal lesion.
CA: A Cancer Journal for Clinicians | 2016
Philippe E. Spiess; Jasreman Dhillon; Adam S. Baumgarten; Peter A.S. Johnstone; Anna R. Giuliano
Answer questions and earn CME/CNE
Urology | 2014
Adam S. Baumgarten; Justin B. Emtage; Richard B. Wilder; Matthew C. Biagioli; Shilpa Gupta; Philippe E. Spiess
INTRODUCTION To describe the technique of injecting Lipiodol in the submucosa of the urinary bladder wall as a novel modality to improve localization of muscle-invasive bladder tumors before image-guided radiation therapy. TECHNICAL CONSIDERATIONS Eight patients underwent submucosal Lipiodol injections at transurethral bladder tumor reresection. A rigid cystoscope with a working port was used to inject Lipiodol into bladder submucosa circumferentially around the tumor bed (2-3 mm from margin of resection). Approximately 20-30 injections were used to demarcate the tumor bed for external beam radiation therapy, which was used as part of a bladder-sparing approach. All patients were diagnosed with clinically localized, high-grade, muscle-invasive carcinoma and were deemed nonsurgical candidates or were unwilling to undergo radical cystectomy. Five of the 8 patients received radiation at our institution. Lipiodol injections (95%) were visible on treatment planning computed tomographic scans and kilovoltage portal images throughout the 7-week course of image-guided radiation therapy. In 2 of 5 patients, the tumor bed based on Lipiodol extended outside a planning target volume that would have been treated with radiation therapy based on cystoscopy reports and computed tomographic scans without Lipiodol. There were no adverse events or treatment-related toxicities secondary to Lipiodol injection. CONCLUSION Intravesical Lipiodol injection is an easy-to-perform technique that is safe and effective. Lipiodol serves as a fiducial marker that improves tumor bed localization for radiation therapy, thereby reducing the likelihood of missing the tumor.
Current Urology Reports | 2014
Tariq S. Hakky; Adam S. Baumgarten; Justin Parker; Yin Zheng; Mike Kongnyuy; Daniel Martinez; Rafael Carrion
A compromise in erectile function is commonly experienced after radical prostatectomy and has been attributed to injury to vascular, neurogenic, and smooth muscle. The concept of rehabilitation after organ injury is not a novel concept and is one that has been applied to all aspects of medicine. Penile rehabilitation has been classically defined as the use of a device or pharmacologic agent to aid erectile function recovery after radical prostatectomy. Here we redefine penile rehabilitation as the use of any device, medication, or intervention to promote male sexual function as a primer before and after any insult to the penile erectile physiologic axis. We also review the epidemiology, rational and current literature on penile rehabilitation after prostatectomy.
International Braz J Urol | 2014
Adam S. Baumgarten; Tariq S. Hakky; Rafael Carrion; Jorge L. Lockhart; Philippe E. Spiess
INTRODUCTION The limitations of traditional ureteral stents in patients with deficiencies in ureteral drainage have resulted in frequent stent exchanges. The implementation of metallic stents was introduced to improve the patency rates of patients with chronic upper urinary tract obstruction, obviating the need for frequent stent exchanges. We report our clinical experiences with the use of metallic ureteral stents in the management of poor ureteral drainage. MATERIALS AND METHODS Fifty patients underwent metallic ureteral stent placement from 2009 to 2012. Stent failure was defined as an unplanned stent exchange, need for nephrostomy tube placement, increasing hydronephrosis with stent in place, or an elevation in serum creatinine. Stent life was analyzed using the Kaplan-Meier methodology, as this was a time dependent continuous variable. A cost analysis was similarly conducted. RESULTS A total of 97 metallic stents were placed among our cohort of patients: 63 in cases of malignant obstruction, 33 in the setting of cutaneous ureterostomies, and 1 in an ileal conduit urinary diversion. Overall, stent failure occurred in 8.2% of the stents placed. Median stent life was 288.4 days (95% CI: 277.4-321.2 days). The estimated annual cost for traditional polymer stents (exchanged every 90 days) was
International Braz J Urol | 2014
J. Wallen; Adam S. Baumgarten; Tim Kim; Tariq S. Hakky; Rafael Carrion; Philippe E. Spiess
9,648-
Orthopedics | 2013
Thomas L. Bernasek; Devanand Mangar; Hesham R. Omar; Steven Lyons; Rachel Karlnoski; Ren Chen; Adam S. Baumgarten; Collin Sprenker; Enrico M. Camporesi
13,128, while the estimated cost for metallic stents was
Clinical Genitourinary Cancer | 2017
Juan Chipollini; Dominic H. Tang; Pranav Sharma; Adam S. Baumgarten; Philippe E. Spiess
4,211-